当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Lin Xu
In chronic kidney disease (CKD) patients, vascular calcification (VC) and cardiac valve calcification (CVC) are the major reasons of increased risk of cardiovascular events. Originally thought to be a passive kind of dead or dying cells, VC and CVC have since been identified as a disease caused by an active and highly controlled cellular process. Several of the processes implicated in VC have recently been identified, and many of them may be exacerbated in CKD patients. FGF-23/Klotho axis, Wnt pathways, PI3K/Akt signalling, P38MAPK signalling pathway, and microRNAs, in particular, have been demonstrated to be disturbed in CKD patients and may have a role in vascular calcification. Moreover, multiple researches confirmed the hazards of CVC in CKD patients as well as the molecular processes behind it. The purpose of this review is to describe the risk variables and pathophysiological processes that may be implicated in the relationship among CKD and VC and CVC development.